scholarly journals 5PSQ-158 Off-label use of pembrolizumab in PD-L1 positive metastatic anaplastic thyroid carcinoma: a case report

2021 ◽  
Author(s):  
SMA Giordano ◽  
M Scaldaferri ◽  
E Caiazza ◽  
F Cattel
Keyword(s):  
Case Report ◽  
Thyroid Carcinoma ◽  
Anaplastic Thyroid Carcinoma ◽  
Off Label Use ◽  
Off Label ◽  
Label Use

CP-032 Off-label use of adalimumab in behÇet’s disease. a case report

2015 ◽  
Vol 22 (Suppl 1) ◽  
pp. A13.3-A14
Author(s):  
MH García Lagunar ◽  
M Gutiérrez Cívicos ◽  
R Guerrero Bautista ◽  
E Ferris Villanueva ◽  
A García Márquez ◽  
...  
Keyword(s):  
Case Report ◽  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Off Label Use ◽  
Behcet's Disease ◽  
Off Label ◽  
Label Use

Off-Label Use of the Edwards Intuity Elite Prosthesis: A Case Report

2019 ◽  
Vol 28 ◽  
pp. S108
Author(s):  
J. Martinelli Nadal ◽  
Fabiano Viana
Keyword(s):  
Case Report ◽  
Off Label Use ◽  
Off Label ◽  
Label Use

scholarly journals Successful free flap salvage surgery with off-label use of Alteplase: A case report, review of the literature and our free flap salvage algorithm

2020 ◽  
Vol 75 ◽  
pp. 398-402
Author(s):  
Fatima Barhoum ◽  
Klaus Tschaikowsky ◽  
Michael Koch ◽  
Markus Kapsreiter ◽  
Matti Sievert ◽  
...  
Keyword(s):  
Case Report ◽  
Free Flap ◽  
Salvage Surgery ◽  
Off Label Use ◽  
Review Of The Literature ◽  
Off Label ◽  
Label Use

scholarly journals Successful free flap revision with off-label use of Alteplase: A case report and review of the literature

2018 ◽  
Author(s):  
F Barhoum ◽  
M Koch ◽  
K Tschaikowsy ◽  
M Sievert ◽  
H Iro ◽  
...  
Keyword(s):  
Case Report ◽  
Free Flap ◽  
Off Label Use ◽  
Review Of The Literature ◽  
Off Label ◽  
Label Use

Off‐label use of aprepitant for scleroderma‐associated nausea and vomiting: A case report

2019 ◽  
Vol 44 (5) ◽  
pp. 805-808
Author(s):  
Bellal B. Jubran ◽  
Jocelyn Bolduc ◽  
Amy Eng ◽  
Melanie Stapleton ◽  
Ben J. Wilson
Keyword(s):  
Case Report ◽  
Nausea And Vomiting ◽  
Off Label Use ◽  
Off Label ◽  
Label Use

scholarly journals 4CPS-172 Off-label use of intralesional cidofovir in recurrent respiratory papillomatosis: a case report

2020 ◽  
Author(s):  
A Ganfornina Andrades ◽  
MDC Jiménez De-Juan ◽  
A Salguero Olid ◽  
MJ Fernández Anguita
Keyword(s):  
Case Report ◽  
Recurrent Respiratory Papillomatosis ◽  
Off Label Use ◽  
Off Label ◽  
Label Use

scholarly journals First experience of off-label use GLE/PIB+SOF in treating a patient with relapse of RNA HCV 1b viremia and RAS R117H in the NS3 region after NS3/4A PI + NS5AI + NS5BI failure of 3D-therapy PTV/R/OBV+DSV in Russia (case report)

2021 ◽  
Vol 13 (1) ◽  
pp. 59-69
Author(s):  
D. L. Sulima ◽  
A. A. Yakovlev ◽  
V. N. Koryagin ◽  
V. A. Larionov ◽  
O. V. Gorchakova ◽  
...  
Keyword(s):  
Case Report ◽  
Clinical Practice ◽  
Virological Response ◽  
Immunological Response ◽  
Off Label Use ◽  
Off Label ◽  
Free Mode ◽  
First Time ◽  
Label Use

For the first time in Russia, a description of a case of full application in clinical practice of a completely interferon-free mode of the 3D-mode GLE/PIB + SOF for the treatment of recurrence of HCV 1b RNA viremia after a primary course of interferonfree therapy in the PTV/r/OBV + DSV mode, which included inhibitors of NS3/4A PI, NS5Ai and NS5Bi, in a patient with combined HCV syndrome is presented. The target result of the repeated course of interferon-free therapy — SVR12 — was achieved despite the presence of significant RAS R117H in the NS3 region of the HCV genome and multiple RASs in the NS3 and NS5A regions, the nature of resistance of which to the corresponding inhibitors of GLE and PIB was unknown. Along with a complete virological response, the treatment also achieved a complete immunological response, which lasted for 12 weeks after the end of the repeated course of interferon-free therapy.

Sign in / Sign up

Export Citation Format

Share Document